Fosphenytoin

Contraindicated

Fosphenytoin Doravirine Pifeltro Reduced doravirine exposure, reduced efficacy of doravirine and an increased risk of doravirine resistance Details Fosphenytoin Fostemsavir Rukobia Reduced temsavir exposure, possible loss of virologic response and an increased risk of QT interval prolongation Details Fosphenytoin Lenacapavir Injection Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Fosphenytoin Lenacapavir Oral Sunlenca Reduced lenacapavir exposure which may result in the loss of therapeutic effect and development of resistance to lenacapavir Details Fosphenytoin Lurasidone Latuda Reduced lurasidone exposure Details Fosphenytoin Nifedipine Adalat® Reduced NIFEdipine exposure and reduced efficacy of NIFEdipine Details

Major

Fosphenytoin Omeprazole Gastrobim Explained Increased phenytoin exposure or fosphenytoin (prodrug of phenytoin), an increased risk of phenytoin or fosphenytoin toxicity (atax... Details Fosphenytoin Amitriptyline Elavil Explained An increased risk of fosphenytoin exposure, reduced TCA exposure and an increased risk of QT interval prolongation Details Fosphenytoin Sertraline Explained Increased risk of fosphenytoin toxicity, reduced efficacy of sertraline and an increased risk of QT interval prolongation Details Fosphenytoin Buprenorphine Belbuca Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Fosphenytoin Relugolix Orgovyx Explained Reduced relugolix exposure, reduced efficacy of relugolix and an increased risk of QT interval prolongation Details Fosphenytoin Simvastatin Flolipid Explained Reduced simvastatin exposure Details Fosphenytoin Abemaciclib Verzenio Explained Decreased abemaciclib plasma concentration Details Fosphenytoin Acalabrutinib Calquence Reduced acalabrutinib exposure Details Fosphenytoin Albendazole Albendamax Reduced albendazole active metabolite exposure Details Fosphenytoin Alpelisib Piqray Reduced alpelisib exposure and reduced efficacy of alpelisib Details Fosphenytoin Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Fosphenytoin Apixaban Eliquis Explained Reduced apixaban exposure, reduced efficacy of apixaban and an increased risk of stroke and other thromboembolic events Details Fosphenytoin Apremilast Otezla Reduced apremilast exposure and an reduced efficacy of apremilast Details Fosphenytoin Arsenic Trioxide Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Fosphenytoin Aripiprazole Injection Abilify Reduced ARIPiprazole or ARIPiprazole lauroxil (prodrug of ARIPiprazole) exposure and an increased risk of QT interval prolongation Details Fosphenytoin Arsenic Trioxide Injection Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Fosphenytoin Asciminib Scemblix Reduced asciminib exposure, reduced efficacy of asciminib, an increased phenytoin or fosphenytoin (prodrug of phenytoin) exposure... Details Fosphenytoin Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Fosphenytoin Aspirin Acuprin® Altered phenytoin or fosphenytoin (prodrug of phenytoin) exposure and an increased risk of phenytoin or fosphenytoin toxicity Details Fosphenytoin Aspirin Rectal Aspirin Altered phenytoin or fosphenytoin (prodrug of phenytoin) exposure and an increased risk of phenytoin or fosphenytoin toxicity Details Fosphenytoin Atogepant Qulipta Reduced atogepant exposure Details Fosphenytoin Avapritinib Ayvakit Reduced avapritinib exposure and reduced efficacy of avapritinib Details Fosphenytoin Azathioprine Azasan An increased risk of hepatotoxicity Details Fosphenytoin Azithromycin AzaSite Increased fosphenytoin exposure and an increased risk of QT interval prolongation Details Fosphenytoin Belumosudil Rezurock Explained Reduced belumosudil exposure and reduced efficacy of belumosudil Details Fosphenytoin Betrixaban Bevyxxa® Decreased betrixaban exposure Details Fosphenytoin Atorvastatin Atorvaliq Reduced atorvastatin exposure and reduced efficacy of atorvastatin Details Fosphenytoin Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Fosphenytoin Abiraterone Abirtega Reduced abiraterone exposure and reduced efficacy of abiraterone Details Fosphenytoin Afatinib Gilotrif Decreased afatinib exposure Details Fosphenytoin Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Fosphenytoin Alfuzosin UroXatral An increased risk of QT interval prolongation Details Fosphenytoin Amlodipine Amvaz® Reduced amLODIPine exposure Details Fosphenytoin Anagrelide Agrylin Decreased anagrelide exposure; increased risk of QT interval prolongation Details